Interestingly, despite the ineffectiveness of ADT in CRPC, the majority of prostate cancers are still driven by AR as a result of several AR reactivation mechanisms [24,25,26,27,28,29,30,31,32,33,34,35,36]. This evidence concerns the gene AR and prostate cancer.